Chand Pasha¹*, Noor Fathima Anjum², Krasimira Stancheva³, Noor Maheen Taj⁴ and Mohammed Sufiyan Pasha⁵

¹Department of General Studies (Chemistry), YELI, Yanbu Industrial College, Royal
Commission for Jubail and Yanbu (RCJY), P. O. Box - 30436, Yanbu – 21477, King-
dom of Saudi Arabia
²Department of Pharmaceutical Chemistry, Farooqia College of Pharmacy, Mysore,
India
³Department of Chemistry, Burgas State University “Prof. Dr. Assen Zlatarov”, 8010,
Bourgas, Bulgaria
⁴Department of Pharmacy Practice, Farooqia College of Pharmacy, Mysore, India
⁵M.B.B.S Student, Siddaganga Medical College and Research Institute, Tumkur,
India

*Corresponding Author: Chand Pasha, Department of General Studies (Chemistry), YELI, Yanbu Industrial College, Royal Commission for Jubail and Yanbu (RCJY), P. O. Box - 30436, Yanbu – 21477, Kingdom of Saudi Arabia.

Received: February 24, 2026 Published: March 31, 2026

Abstract

A rapid spectrophotometric method has been described for determining acyclovir in pharmaceutical dosage forms by diazotization and coupling reaction. In this method, coupling agents such as m-dihydroxybenzene or 2-nitro-1-naphthol reacts with diazonium compound of acyclovir to produce colored azo products with maximum absorption at 462 nm and 468 nm. The calibration graph was discovered to be linear from 2.0 - 18.8 μgmL-1 or 3.8 – 24.2 μgmL-1 when diazonium compound of acyclovir coupled with m-dihydroxybenzene or 2-nitro-1-naphthol. The molar absorptivity and Sandell’s sensitivity of acyclovir with m-dihydroxybenzene or acyclovir with 2-nitro-1-naphthol azo dyes were 5.399×104 L mol-1cm-1 or 3.600×104 Lmol-1cm-1 and 6.249×10-3 μgcm-2 or 9.375×10- 3 μgcm-2 respectively. The results demonstrate that the reaction yielded a stable product and that the suggested approach is accurate, precise, and reasonably priced. The method works well in determining acyclovir in pharmaceutical samples.

Keywords: Spectrophotometry; Diazotization; Acyclovir; m-Dihydroxybenzene; 2-Nitro-1-naphthol

References

1. De C E and Field H J. "Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy". British Journal of Pharmacology1 (2006): 1-11. 
2. "Acyclovir". The American Society of Health-System Pharmacists. Archived from the original on 2015-01-05 (2015).
3. Rafailidis PI., et al. “Antiviral treatment for severe EBV infections in apparently immunocompetent patients". Journal of Clinical Virology3 (2010): 151-157.
4. Corey L., et al. “Blind Controlled Trial of Topical Acyclovir in Genital Herpes Virus Infections”. American Journal of Medicine 73 (1982): 326-334.
5. Keeney RE., et al. “Acyclovir tolerance in human”. American Journal of MedicineA (1982): 176-181.
6. Thin RN. “Management of Genital Herpes Simplex Infections”. American Journal of Medicine 85 (1988): 3-6.
7. Wagstaff JA., et al. “Acyclovir: A reappraisal of its antiviral activity, Pharmacokinetic properties and therapeutic efficacy”. Drugs1 (1994): 153-205.
8. Brien OJ and Campoli RJ. “Acyclovir, An updated review of its antiviral activity, Pharmacokinetic properties and therapeutic efficacy”. Drugs 37 (1989): 233-309.
9. Gnann JW., et al. “Acyclovir Mechanism of Action, Pharmacokinetics, Safety and Clinical Applications”. Pharmacotherapy 3 (1983): 275-283.
10. Whitley RJ., et al. “Pharmacokinetics of acyclovir in humans following intravenous administration. A model for the development of parenteral antivirals”. American Journal of Medicine 73 (1982): 165-171.
11. Sheribah ZA., et al. “Stability indicating polarographic determination of acyclovir through chelation with nickel (II)”. Journal of AOAC International2 (2009): 419-427.
12. Blum MR., et al. “Overview of Acyclovir Pharmacokinetic Disposition in Adults and Children”. American Journal of Medicine 73 (1982): 106-192.
13. Quin RP., et al. “A sensitive radioimmunoassay for the antiviral agent BW 248U (9- (2- hydroxyethoxymethyl) guanine)”. Analytical Biochemistry 98 (1979): 318-328.
14. Yu L and Xiang B. “Quantitative determination of acyclovir in plasma by near infrared spectroscopy”. Microchemistry Journal1 (2008): 63-66.
15. Su-hwei C and Yuan-han Y. “Rapid determination of acyclovir in plasma and cerebrospinal fluid by micellar electrokinetic chromatography with direct sample injection and its clinical application”. Electrophoresis 27 (2006): 819-826.
16. Battermann GCK., et al. “HPLC analysis of active ingredients of pharmaceuticals”. Labor Praxis 30 (1998): 32-34.
17. Pramar Y., et al. “Quantitation of Acyclovir in Pharmaceutical Dosage forms using High-Performance Liquid Chromatography”. Drug Development and Industrial Pharmacy 16 (1990): 1687-1695.
18. Dubhashi SS and Vavia PR. “Stability indicating reversed-phase HPLC method for acyclovir”. Indian Drugs 37 (2000): 464-468.
19. Land G and Bye A. “Simple high performance liquid chromatographic method for the analysis of 9-[ (2-hidrohsiethoxy)methyl] guanine (acyclovir) in human plasma and urine”. Journal of Chromatography 224 (1981): 51-58.
20. Kourany E and Cyr TD. “Determination of acyclovir (Zovirax) and guanine by microbore high-performance liquid chromatography with confirmation by atmospheric pressure chemical ionization mass spectrometry”. Canadian Journal of Applied Spectroscopy 40 (1995): 155-159.
21. Kamel AM., et al. “Effects of Mobile-phase Additives, Solution pH, Ionization Constant, and Analyte Concentration on the Sensitivity and Electrospray Ionization Mass Spectra of Nucleoside Antiviral Agents”. Analytical Chemistry 71 (1999): 5481-5492.
22. Testereci H., et al. “The determination of acyclovir in sheep serum, human serum, saliva and urine by HPLC”. East Journal of Medicine 2 (1998): 62-66.
23. Macka M., et al. “Determination of acyclovir in blood serum and plasma by micellar liquid chromatography with Fluoremetric detection”. Journal of Chromatography11 (1993): 2359-2386.
24. Mascher H., et al. “New, high sensitivity high-performance liquid chromatographic method for the determination of acyclovir in human plasma, using Fluoremetric detection”. Journal of Chromatography 583 (1992): 122-127.
25. Jankowski A., et al. “Determination and pharmacokinetics of acyclovir after ingestion of suspension form”. Journal of Pharmaceutical and Biomedical Analysis 1-2 (1998): 249-254.
26. Basavaiah K and Prameela HC. “Simple spectrophotometric determination of acyclovir in bulk drug and formulations”. Farmaco 57 (2002): 443-449.
27. El-Din MK., et al. “Spectrophotometric determination of acyclovir and ribavirin in their dosage forms”. Journal of AOAC International 3 (2006): 631-641.
28. Sultan, M. 2003. Spectrophotometric determination of acyclovir in some pharmaceutical formulations”. II Farmaco11 (2003): 865-870.
29. Mustafa AA., et al. “Spectrophotometric Determination of Acyclovir and Amantadine Hydrochloride through Metals Complexation”. Journal of Analytical Chemistry1 (2004): 33-38.
30. Chakraborty R., et al. “Spectrophotometric determination and validation of Acyclovir”. Archives of Applied Science Research1 (2011): 328-332.
31. Daabees HG. “The use of derivative spectrophotometry for the determination of acyclovir and diloxamide furoate in the presence of impurity or degradation product”. Analytical Letter 31 (1998): 1509-1522.
32. Mahrous MS., et al. “Use of differential spectrophotometry for determination of cytarbine and acyclovir in their dosage forms”. Analytical Letter 25 (1992): 1491-1501.
33. Ukpe A and Johnson OO. “Spectrophotometric determination of acyclovir after its reaction with ninhydrin and ascorbic acid”. Journal of Applied Pharmaceutical Science 4 (2015): 65-69.
34. Levachkova YV., et al. “Spectrophotometric determination of acyclovir in the suppository”. Der Pharma Chemica2 (2016): 356-360.
35. Bhupinder K and Manish G. “Spectrophotometric Determination of Acyclovir In Various Solvents. International Journal of Information and Computing Science9 (2018): 99-105.
36. Akshata L., et al. “UV Spectrophotometric Analysis and Validation of Acyclovir in Solid Dosage form”. International Journal of Current Pharmaceutical Research 12 (2020): 100-103.
37. Wisam TH and Sarhan AS. “Spectrophotometric determination, analysis and validation of acyclovir on Solid Dosage Form”. International Journal of Medicine and Health (IJMH)2 (2024): 6-13.

Citation

Citation: Chand Pasha., et al. “Development of an Antiviral Drug - Acyclovir in both Pure and Pharmaceutical Forms Using a Rapid Spectrophotometric Method". Acta Scientific Pharmaceutical Sciences 10.4 (2026): 55-61.

Copyright

Copyright: © 2026 Chand Pasha., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.